The pathogenic role of IL-1β is further confirmed by the recent Canakinumab Antiinflammatory Thrombosis Outcome Study, where targeting IL-1β led to a significantly lower rate of recurrent cardiovascular events (35). Here, IL1B is linked to deep vein thrombosis.